| Literature DB >> 28233806 |
Ting Xu1,2, Jing-Yu Gu1, Xin-Hua Ye3, Shu-Hang Xu4, Yang Wu5, Xin-Yu Shao6, De-Zhen Liu7, Wei-Ping Lu7, Fei Hua5, Bi-Min Shi6, Jun Liang8, Lan Xu9, Wei Tang2, Chao Liu4, Xiao-Hong Wu1.
Abstract
To evaluate the impact of thyroid nodule sizes on the diagnostic performance of thyroid imaging reporting and data system (TIRADS) and ultrasound patterns of 2015 American Thyroid Association (ATA) guidelines. Total 734 patients with 962 thyroid nodules were recruited in this retrospective study. All nodules were divided into three groups according to the maximal diameter (d < 10 mm, d = 10-20 mm and d > 20 mm). The ultrasound images were categorized based on TIRADS and ATA ultrasound patterns, respectively. A total of 931 (96.8%) and 906 (94.2%) patterns met the criteria for TIRADS and ATA ultrasound patterns. The AUC (0.849) and sensitivity (85.3%) of TIRADS were highest in d = 10-20 mm group. However, ATA had highest AUC (0.839) and specificity (89.8%) in d > 20 mm group. ATA ultrasound patterns had higher specificity (P = 0.04), while TI-RADS had higher sensitivity (P = 0.02). In nodules d > 20 mm, the specificity of ATA patterns was higher than TIRADS (P = 0.003). Our results indicated that nodule sizes may influence the diagnostic performance of TIRADS and ATA ultrasound patterns. The ATA patterns may yield higher specificity than TIRADS, especially in nodules larger than 20 mm.Entities:
Mesh:
Year: 2017 PMID: 28233806 PMCID: PMC5324396 DOI: 10.1038/srep43183
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Diagram of the study group.
Clinical features of the study population and basic characters of the nodules.
| Features | <10 mm | 10–20 mm | >20 mm | ||
|---|---|---|---|---|---|
| Pathology | Benign | 184 | 157 | 246 | 0.000 |
| Malignant | 173 | 132 | 70 | ||
| Sex | Male | 46 | 54 | 56 | 0.000 |
| Female | 181 | 183 | 214 | ||
| Nodularity | Single | 140 | 147 | 180 | 0.000 |
| Multiple | 217 | 142 | 136 | ||
| Lymphadenopathy | Present | 277 | 219 | 254 | 0.422 |
| Absent | 80 | 70 | 62 | ||
| Location | Isthmus | 15 | 12 | 6 | 0.189 |
| Left | 174 | 126 | 161 | ||
| Right | 168 | 151 | 149 | ||
| Age (year) | 45.7 ± 12. 5 | 46.4 ± 13.6 | 48.2 ± 13.2 | 0.147 | |
| FT3 (pmol/L) | 5.2 ± 3.7 | 4.8 ± 1.6 | 5.0 ± 3.2 | 0.010 | |
| FT4 (pmol/L) | 16.6 ± 11.3 | 15.5 ± 5.6 | 14.9 ± 3.8 | 0.173 | |
| TSH (mIU/L) | 2.2 ± 1.8 | 2.8 ± 2.8 | 2.8 ± 6.9 | 0.087 | |
The malignancy rates of TI-RADS classifications.
| n | Surgery (%) | Follow-up (%) | Benign (%) | Malignant (%) | ||
|---|---|---|---|---|---|---|
| 0.000 | ||||||
| 2 | 4 | 2 (50.0) | 2 (50.0) | 4 (100.0) | 0 | |
| 3 | 131 | 91 (69.5) | 40 (30.5) | 103 (78.6) | 28 (21.4) | |
| 4A | 105 | 83 (79.0) | 22 (21.0) | 48 (45.7) | 57 (54.3) | |
| 4B | 98 | 77 (78.6) | 21 (21.4) | 22 (22.4) | 76 (77.6) | |
| 5 | 8 | 8 (100.0) | 0 | 0 | 8 (100.0) | |
| Total | 346 | 261 (75.4) | 85 (24.6) | 177 (51.2) | 169 (48.8) | |
| 0.000 | ||||||
| 2 | 2 | 1 (50.0) | 1 (50.0) | 2 (100.0) | 0 | |
| 3 | 125 | 97 (77.6) | 28 (22.4) | 107 (85.6) | 18 (14.4) | |
| 4A | 80 | 69 (86.3) | 11 (13.7) | 35 (43.8) | 45 (56.2) | |
| 4B | 56 | 56 (100.0) | 0 | 5 (8.9) | 51 (91.1) | |
| 5 | 14 | 14 (100.0) | 0 | 0 | 14 (100.0) | |
| Total | 277 | 237 (85.6) | 40 (14.4) | 149 (53.8) | 128 (46.2) | |
| 0.000 | ||||||
| 2 | 29 | 10 (34.5) | 19 (65.5) | 29 (100.0) | 0 | |
| 3 | 183 | 107 (59.3) | 76 (40.7) | 167 (91.5) | 16 (8.5) | |
| 4A | 51 | 26 (51.0) | 25 (49.0) | 35 (68.6) | 16 (31.4) | |
| 4B | 40 | 37 (92.5) | 3 (7.5) | 11 (27.5) | 29 (72.5) | |
| 5 | 5 | 5 (100.0) | 0 | 0 | 5 (100.0) | |
The comparison of TI-RADS classifications and 2015 ATA guidelines in diagnostic value.
| Cut-off | AUC (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | |
|---|---|---|---|---|---|---|
| TI-RADS classification | 4A | 0.753 (0.716–0.805) | 82.5 (76.3–88.7) | 57.7 (49.8–65.6) | 66.4 (59.1–72.7) | 77.3 (68.7–84.5) |
| 2015 ATA guidelines | High suspicious for malignancy | 0.721 (0.670–0.772) | 80.5 (73.2–86.2) | 63.7 (55.5–71.2) | 69.2 (62.0–75.8) | 76.0 (67.6–83.1) |
| TI-RADS classification | 4A | 0.849 (0.802–0.891) | 85.3 (78.4–91.3) | 72.6 (64.7–79.8) | 73.5 (65.5–80.4) | 85.4 (77.7–91.0) |
| 2015 ATA guidelines | High suspicious for malignancy | 0.813 (0.749–0.849) | 75.8 (66.0–82.9) | 79.9 (72.0–86.1) | 76.5 (68.3–84.0) | 77.6 (70.8–85.1) |
| TI-RADS classification | 4A | 0.836 (0.790–0.876) | 76.9 (64.8–86.5) | 80.6 (75.0–85.4) | 52.1 (41.6–62.4) | 92.7 (88.3–95.9) |
| 2015 ATA guidelines | High suspicious for malignancy | 0.839 (0.792–0.879) | 70.8 (58.2–81.4) | 89.8 (85.1–93.4) | 66.7 (54.3–77.6) | 91.4 (86.9–94.8) |
The malignancy rates of 2015 ATA guidelines ultrasound patterns.
| n | Surgery (%) | Follow-up (%) | Benign (%) | Malignant (%) | ||
|---|---|---|---|---|---|---|
| 0.000 | ||||||
| Very low suspicion | 5 | 4 (80.0) | 1 (20.0) | 4 (80.0) | 1 (20.0) | |
| Low suspicion | 35 | 23 (65.7) | 12 (34.3) | 29 (82.9) | 6 (17.1) | |
| Intermediate suspicion | 107 | 78 (72.9) | 29 (27.1) | 82 (76.6) | 25 (23.4) | |
| High suspicion | 193 | 155 (80.3) | 38 (19.7) | 57 (29.5) | 136 (70.5) | |
| Total | 340 | 260 (76.5) | 80 (23.5) | 172 (50.6) | 168 (49.4) | |
| 0.000 | ||||||
| Very low suspicion | 9 | 4 (44.4) | 5 (55.6) | 8 (88.9) | 1 (11.1) | |
| Low suspicion | 60 | 35 (58.3) | 25 (41.7) | 53 (88.3) | 7 (11.7) | |
| Intermediate suspicion | 76 | 50 (65.8) | 26 (34.2) | 54 (71.1) | 22 (28.9) | |
| High suspicion | 124 | 100 (80.6) | 24 (19.4) | 29 (23.4) | 95 (76.6) | |
| Total | 269 | 189 (70.3) | 80 (29.7) | 144 (53.5) | 125 (46.5) | |
| 0.000 | ||||||
| Very low suspicion | 24 | 16 (66.7) | 8 (33.3) | 24 (100.0) | 0 (0) | |
| Low suspicion | 116 | 78 (67.2) | 38 (32.8) | 108 (93.1) | 8 (6.9) | |
| Intermediate suspicion | 88 | 58 (65.9) | 30 (34.1) | 76 (86.4) | 12 (13.6) | |
| High suspicion | 69 | 60 (87.0) | 9 (13.0) | 23 (33.3) | 46 (66.7) | |
| Total | 297 | 212 (71.4) | 85 (28.6) | 231 (77.8) | 66 (22.2) |